dlbcl

Showing NaN - NaN of 10

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)

Not yet recruiting
  • Phase 1
  • +9 more
  • Oral MRT-2359
  • Scottsdale, Arizona
  • +7 more
Sep 16, 2022

Advanced Solid Tumor, DLBCL Trial in United States (RNK05047)

Recruiting
  • Advanced Solid Tumor
  • DLBCL
  • Atlanta, Georgia
  • +3 more
Aug 23, 2022

DLBCL Trial in United States (MB-CART2019.1)

Recruiting
  • DLBCL
  • MB-CART2019.1
  • Gilbert, Arizona
  • +14 more
Jun 17, 2022

Advanced Solid Tumor, NSCLC, Melanoma Trial in United States (AB308, Zimberelimab)

Recruiting
  • Advanced Solid Tumor
  • +9 more
  • Phoenix, Arizona
  • +20 more
May 2, 2022

Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)

Recruiting
  • Large B-cell Lymphoma
  • DLBCL
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 30, 2022

Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL Trial in Australia, Korea, Republic of, United States (IGM-2323)

Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +12 more
Mar 24, 2022

B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

Recruiting
  • B-ALL
  • +10 more
  • 131-I Apamistamab
  • CAR T-cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in United Kingdom, United States (AUTO3)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • AUTO3
  • Duarte, California
  • +10 more
Nov 19, 2021

Non-Hodgkin Lymphoma, DLBCL, Diffuse Large B-cell Lymphoma Trial in United States (SGN-CD19B)

Terminated
  • Non-Hodgkin Lymphoma
  • +3 more
  • Birmingham, Alabama
  • +15 more
Aug 9, 2018